FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease
Phase 1
- Conditions
- Peripheral Arterial DiseaseStenosisIntermittent Claudication
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- CardioVascular BioTherapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00424866
- Locations
- 🇺🇸
CVBT Info, Dallas, Texas, United States
FGF-1 for Topical Administration for the Treatment of Diabetic or Venous Stasis Ulcers
Phase 1
Completed
- Conditions
- DiabetesVenous Stasis UlcersChronic Wounds
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- CardioVascular BioTherapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT00425178
- Locations
- 🇺🇸
Warren General Hospital, Warren, Pennsylvania, United States
Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease
Phase 2
- Conditions
- Coronary DiseaseCoronary Heart DiseaseMyocardial IschemiaCoronary Arteriosclerosis
- Interventions
- Combination Product: PlaceboCombination Product: Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low doseCombination Product: Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- CardioVascular BioTherapeutics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT00117936
© Copyright 2025. All Rights Reserved by MedPath